Skip to main content
. Author manuscript; available in PMC: 2009 Oct 5.
Published in final edited form as: Ann Intern Med. 2008 Nov 4;149(9):601–611. doi: 10.7326/0003-4819-149-9-200811040-00003

APPENDIX FIGURE 1. Study Design.

APPENDIX FIGURE 1

Year 1: In each of 3 cohorts [23 men, 25 women on HRT and 17 women off HRT], 2/3 received oral MK-677 (25 mg daily) and 1/3 received placebo. At the end of year 1, MK-677-treated subjects were randomized to continue on MK-677 (Group 1) or change to placebo (Group 2); the placebo-treated subjects were given MK-677 treatment in year 2 (Group 3).